Lilly pays Insilico $115M for AI drug discovery
Eli Lilly paid Insilico Medicine $115 million upfront for global rights to novel oral therapeutics from Insilico's AI platform; the MedCity News column names mitochondrial dysfunction among future AI drug targets, linking to the Eternal Search glossary entry.
$115 million upfront. That is what Eli Lilly paid Insilico Medicine for global rights to develop and commercialize novel oral therapeutics from Insilico's AI platform (Neil Panchal, MedCity News column, April 2026). The remaining $2.63 billion is tied to milestones and royalties. Among future targets for such drugs, the author names mitochondrial dysfunction. The article cites no clinical data on this target. The term has an entry in the Eternal Search glossary.
Open the related Eternal Search page
Sources
[1] LOISIUM Langenlois // Wine & Spa Hotel
[2] AI Drug Discovery Is Reshaping Longevity Medicine. Is Your Practice Ready? - MedCity News
[3] LOISIUM // Aktuelle Angebote
[4] LOISIUM Langenlois // Spa & Beauty: Day Spa Packages - SUMMER …
[5] LOISIUM Langenlois // Spa & Beauty
[6] LOISIUM Hotel Langenlois Kulinarik-Angebot
The Lilly-Insilico deal is a concrete, dollar-denominated event in AI drug discovery. The MedCity News column names mitochondrial dysfunction among expected future targets, creating a natural bridge to the Eternal Search glossary page for readers who want to understand the biology behind the term. The post keeps the distinction clear: the $115M is a fact, mitochondrial dysfunction as a drug target is the author's forecast, and clinical validation has not been cited.